

GENETIC ENGINEERING AND THE MODERN SURVIVAL OF LIFE MECHANISMS

Dr. Uttam Prasad Panigrahy (Corresponding Author), **Dr. Aniketa Sharma, ***Renzon Daniel Cosme Pecho, *Priyank Purohit, *****Dr. Vijay Pratap Raghuvanshi, ***** Mr Abhijit Gupta**

*M. Pharma, Ph.D, Associate Professor, Department of Pharmaceutical Analysis, Faculty of Pharmaceutical sciences, Assam Down Town University, Sankar Madhab Path, Gandhi Nagar, Panikhaiti, Guwahati, Assam-781026, India,

**Assistant Professor, Department of Medicine, DR. YSR Government Medical College, Nahan, District-Sirmour, H.P., India,

***Professor, Department of Biochemistry, Universidad San Ignacio de Loyola, La Molina 1524, Lima, Peru,

****Assistant Professor, Department of Pharmacy, Graphic Era Hill University, Dehradun, India,

*****Associate Professor, Department of Facilities and Hygiene Management, Delhi Skill and Entrepreneurship University, Delhi, India,

*****Assistant Professor, Institute of Biotechnology, Chandigarh University, Punjab, India,

Abstract

In this research genetic engineering is used for modern life. The mechanism of this technique can be evaluated through the review of the articles. With the help of the modification of the gene arrangement gene therapy can be applied. The reduction of diseases that is mainly hereditary or genetic can be well treated with the help of this technique. With the help of genetic modification, the immune system of the body can be improved. The treatment of the expression of the oncogenes for the reduction of cancer can be possible. The process of genetic engineering through the T-cells has been evaluated in this research. Based on the research it can also be stated that the improvement of the shelf-life of food can be possible with the help of this technique. Through genetic modification, the improvement of the function of T-cells can be done that is effective to fight against cancer.

Keywords: *Malignancies, Lymphoblastic leukemia, CRISPR-Cas, Gene gun, CAR-T cells, anti-angiogenesis, oncogenes.*

TABLE OF CONTENTS

Introduction.....	6070
Review of literature.....	6071
Materials and Methodology	6073
Results and Discussion	6074
Conclusion and future scope.....	6077
Recommendations.....	6078
Reference list	6079
Appendices.....	6080

Introduction

Genetic engineering is very effective in modern life. Through the help of this technique, scientists can be involved in the changes in the sequence of the genome. With this technique due to the changes in the

genome, the termination of certain diseases can be possible. Different types of diseases like diabetes and cystic fibrosis can be treated by the use of genetic engineering. "Genetic engineering" can provide medical benefits for the repairing of the genetic defects that can be associated with hereditary diseases. The modification of the gene can also apply to the development of pharmaceuticals, and food production improvement (McSweeney *et al.* 2021). With the introduction of a new gene, the modification of the gene can be possible which can hinder the growth of cancer cells. In this research by review of the articles and the identification of the method of this process, the result of these techniques can be demonstrated.

Review of literature

According to the review of the article by the author, Yamamoto *et al.* 2019, the transfer of "adoptive cells" which is ACT utilizing hereditarily designed lymphocytes has turned into the "standard of care" for patients with immovable B-cell malignancies. This is including adolescent intense lymphoblastic leukemia (Romei *et al.* 2019). Hereditary designing of Fas variations weakens FADD restricting to work as predominant negative receptors (DNRs). This also forestalls FasL-prompted apoptosis in immune system microorganisms approved by "FAS". A few factors might impact the achievement or disappointment of immune system microorganisms moved to intercede malignant growth relapse in patients whose cancer cells consistently express an objective antigen. Immune system microorganisms co-designed with Fas DNR and the White blood cell receptor or mosaic antigen receptor showed expanded perseverance after ACT, bringing about the unrivaled enemy of growth adequacy against hematologic and strong diseases has framed (Yamamoto *et al.* 2019). Despite the expanded life expectancy, Fas DNR-altered White blood cells do not go through unusual extension or evoke autoimmunity. Consequently, natural White blood cell disturbance of Fas announcing hereditary designing addresses a possible general procedure to work on the viability of ACT in many human malignancies. *[Referred to Appendix 1]*




Figure 1: Epenjenitics

(Source: Yamamoto *et al.* 2019)

According to the review of the article by the author, Chen *et al.* 2019, homologous recombination is the trading of nucleotide arrangements between two DNA atoms with comparative or indistinguishable groupings. It is a characteristic natural occasion and has been utilized in an original procedure for phage genome designing. This traditional hereditary procedure has been utilized as a standard method for producing "mutant" phages with explicit aggregates by joining or isolating mutation from two-parent phages (Chen *et al.* 2019). The offspring phages were then evaluated for the ideal phenotypes, and the recombinants with the proper aggregates were sanitized for additional examination. This strategy is chiefly used to trade or consolidate aggregates of parent phages. It cannot explicitly adjust the designated site in the phage genome, which confines the utilization of this technique.




Figure 2: CRISPR-Cas-based genetic engineering

(Source: Chen *et al.* 2019)

Materials and Methodology

The use of the plasmid can be mentioned as the most common method in genetic engineering. The plasmid strategy utilizes little roundabout bits of DNA particles to change microorganisms, like “bacteria”. The plasmid is set in a container with a compound that cuts the plasmid into little pieces. A little part of the plasmid is then brought into the microbes, where the DNA consolidates inside the cell and is balanced out. A live bacterial culture is then ready with the recently framed plasmids, after which the plasmids enter the bacterial cell and start to replicate. During this cycle, the plasmid incorporates new anti-microbial obstruction qualities that recognize microscopic organisms with plasmids from microorganisms without plasmids (Li *et al.* 2019). CRISPR-Cas can be mentioned as another hereditary designing innovation that permits to change of the hereditary material of microorganisms, infections, plants, and creatures. Besides this, the use of the “gene-gun” method can be applied. With the help of the “DNA-coated” metal particle, the DNA can be placed at the target region.




Figure 3: Genetic Implementation Methodology

(Source: https://sphweb.bumc.bu.edu/otlt/mph-modules/ph/gmos/gmos_print.html)

Results and Discussion

Cancer immunotherapy can be provided by the genetic modification of T-cells. Within the immune system, T-cells are involved in protecting from the pathogen in the human body. With the help of the specific recognition system of the T-cells receptors, the clearance of mutant cells from the body can be possible (Ullah *et al.* 2019). Based on the recognition method, "cancer immunotherapy" improves the antitumor adequacy of "lymphocytes" by actuating safe designated spot hindrance. It also broadens versatile resistance by working with the exchange of transgenic "White blood cells". The use of "TCR-Lymphocytes" as a "novel" receptive immunotherapy has shown empowering brings about the therapy of a few high-level diseases. TCR-Lymphocytes can distinguish more "sensitive" intracellular antigens through the MHC system.




Figure 4: Cancer Immunotherapy

(Source: <https://blog.crownbio.com/personalized-cancer-immunotherapy>)

Clinical examinations utilizing "TCR-T cells" system microorganisms to treat metastatic melanoma, synovial sarcoma, and colorectal malignant growth have made amazing progress. The justification for the moderate clinical viability of "CAR-T cells" recently used to treat strong growths is multifactorial. Not at all like hematologic malignancies, have strong cancers presented different hindrances to "CAR-T cells" because of brief or inadequate penetration (Quiet *al.* 2019). As a principal essential for helpful viability, "CAR-T cells" microorganisms should be conveyed to the "tumor" sore. After amassing close by, they should enter the growth. After relocating into strong growth injuries, "CAR-T cells" should beat threatening immunosuppressive elements to prompt explicit cytotoxicity.




Figure 5: “Immunosuppressive microenvironment” within solid tumors

(Source: Li et al. 2019)

Genetically, the T-cells are equipped with "chimeric antigen receptors" that can be abbreviated as "TCRs". This is shown effectiveness in the treatment of a few "hematologic malignancies". Despite the adequacy of T-cells, the treatment of solid tumors can be away from the satisfactory stages of the treatment. In this research, the improvement of hereditarily designed lymphocytes depicts the latest investigations of hereditarily designed T-cells for disease immunotherapy. This also examines techniques for the advancement of malignant growth immunotherapy. The way of function of the T-cells is effective to work on the exhibition of this immune system in the battle against malignant growth.




Figure 6: CAR-T Therapy

(Source <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/car-t-cell-therapy>)

Conclusion and future scope

From the overall analysis, it can be stated that with the help of genetic engineering gene therapy can be possible. If a gene with specific coding is responsible for the presence of the activation of the oncogenes, its expression can be changed by the alteration of the coding of the gene. Due to the changes in the gene sequence through alteration, the expression of the proteins as well as its production can be changed. Through this, genetics can be modified by the researcher which is effective for the strengthening of the immune system of the cancer cells and weakening of cancer disease can be possible.




Figure 7: Future Scope in Genetic Engineering

(Source: https://www.researchgate.net/figure/Employment-of-CRISPR-Cas-Systems-in-the-Central-Dogma-of-Plant-Biology_fig3_344151544)

Genes are also used for the prevention of blood vessels from “forming”. This makes cancer starve which can be called "anti-angiogenesis". Utilizing qualities of healthy cells from the results of treatment takes into consideration higher dosages of chemotherapy and radiation to be conveyed. With "genetic engineering" it is feasible to concentrate on the elements of qualities and give antibodies, life-saving medications, and all the more like decreasing the requirement for pesticides (Saini *et al.* 2020). It can try and track down a remedy for malignant growth. Later on, quality treatments might be utilized to forestall, treat, or fix specific hereditary problems, for example, "alpha-1 antitrypsin inadequacy", "cystic fibrosis", "beta-thalassemia", "hemophilia", as well as sickle cell infection. In this way, the "quality of life" of the people can be improved with the reduction of morbidity and mortality rate.

Recommendations

From the research, it can be stated that the improvement of genetic engineering can be possible by the application of this technique. With the application of this technique within the plant cells the use of pesticides can be reduced. This is effective for the reduction of the effect of pesticides. This technique is also effective for the formation of new types of medicines that is also effective for the reduction of the morbidity rate of people (Mascellino *et al.* 2021).




Figure 8: Impact Genetic Engineering

(Source: <https://www.cell.com/trends/plant-science/fulltext/S1360-1385%2821%2900069-8>)

The shelf life of the food can also be improved by the use of this technique. Ethics are required to be maintained at the time of application of the technique within the human genome. It can be recommended that the performance level of athletes can also be improved in this way.

Reference list

Journals

Chen, Y., Batra, H., Dong, J., Chen, C., Rao, V.B. and Tao, P., 2019. Genetic engineering of bacteriophages against infectious diseases. *Frontiers in microbiology*, 10, p.954.

Li, D., Li, X., Zhou, W.L., Huang, Y., Liang, X., Jiang, L., Yang, X., Sun, J., Li, Z., Han, W.D. and Wang, W., 2019. Genetically engineered T cells for cancer immunotherapy. *Signal Transduction and Targeted Therapy*, 4(1), p.35.

Mascellino, M.T., Di Timoteo, F., De Angelis, M. and Oliva, A., 2021. Overview of the main anti-SARS-CoV-2 vaccines: mechanism of action, efficacy and safety. *Infection and drug resistance*, pp.3459-3476.

McSweeney, K.R., Gadanec, L.K., Qaradakh, T., Ali, B.A., Zulli, A. and Apostolopoulos, V., 2021. Mechanisms of cisplatin-induced acute kidney injury: Pathological mechanisms, pharmacological interventions, and genetic mitigations. *Cancers*, 13(7), p.1572.

Qiu, Z., Egidi, E., Liu, H., Kaur, S. and Singh, B.K., 2019. New frontiers in agriculture productivity: Optimised microbial inoculants and in situ microbiome engineering. *Biotechnology advances*, 37(6), p.107371.

Romeis, J., Naranjo, S.E., Meissle, M. and Shelton, A.M., 2019. Genetically engineered crops help support conservation biological control. *Biological Control*, 130, pp.136-154.







Saini, D.K., Chakdar, H., Pabbi, S. and Shukla, P., 2020. Enhancing production of microalgalbiopigments through metabolic and genetic engineering. *Critical reviews in food science and nutrition*, 60(3), pp.391-405.

Ullah, M., Liu, D.D. and Thakor, A.S., 2019. Mesenchymal stromal cell homing: mechanisms and strategies for improvement. *Iscience*, 15, pp.421-438.

Yamamoto, T.N., Lee, P.H., Vodnala, S.K., Gurusamy, D., Kishton, R.J., Yu, Z., Eidizadeh, A., Eil, R., Fioravanti, J., Gattinoni, L. and Kochenderfer, J.N., 2019. T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. *The Journal of clinical investigation*, 129(4), pp.1551-1565.

Appendices

Appendix 1: Overexpression of human TMEs



(Source: Yamamoto et al. 2019)